A large variety of oncogenes and tumor suppressors (e.g. MYC, KRAS, HIF-1α stabilization, mTOR, P53, PTEN etc.)have been found to influence the glutamine metabolism and its effector pathways, emphasizing the importance of the glutamine pathway in tumor cell development, expansion and metastatic properties (113). This evidence concerns the gene KRAS and neoplasm.